Company SanBio Company Limited

Equities

4592

JP3336750009

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Sales per region

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-26 EDT			5-day change	1st Jan Change
419 ^JPY	+1.45%		-0.95%	-40.31%

03-19	SanBio Eyes Approval for Brain Injury Treatment Drug SB623 By March	MT
03-19	Jefferies Adjusts SanBio’s Price Target to 270 Yen From 310 Yen, Keeps at Underperform	MT

SanBio Co Ltd is engaged in the regenerative cell business using allogeneic stem cells. The Company has the research and development base in the United States and conducts research, development, manufacture and sale of regenerative cell medicines in Japan. The Company aims to sell therapeutic agents for diseases with high unmet medical needs, mainly in diseases of the central nervous system. It is involved in the manufacture, development, non-clinical studies, clinical trials of technologies introduced from research institutes such as universities. The Company has five regenerative cell drugs, including the main product candidate SB623 (nerve regenerative cells), SB618 (function-enhancing type & Mesenchymal stem cells), SB308 (muscle stem cells), MSC1 (mesenchymal stem cells), and MSC2 (mesenchymal stem cells).

Number of employees: 65

Managers	Title	Age	Since
Keita Mori CEO	Chief Executive Officer	56	13-02-26
Shinya Hirata CTO	Chief Tech/Sci/R&D Officer	-	-
Chris sanbio Horan CTO	Chief Tech/Sci/R&D Officer	-	-
Yoshihiro Kakutani ADM	Chief Administrative Officer	-	-
Naoki Tsukahara HRO	Human Resources Officer	-	-

Members of the board	Title	Age	Since
Noboru Kotani BRD	Director/Board Member	67	13-02-28
Keita Mori CEO	Chief Executive Officer	56	13-02-26
Toru Kawanishi CHM	Chairman	56	13-02-26

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	0	68,630,002	48,833,077 ( 71.15 %)	278 ( 0.000405 %)	71.15 %

Name	Equities	%	Valuation
Toru Kawanishi 17.81 %	12,221,186	17.81 %	36 M ¥
Keita Mori 8.739 %	5,997,284	8.739 %	18 M ¥
TEIJIN LIMITED 1.446 %	992,477	1.446 %	3 M ¥
Hitoshi Imamura 0.7660 %	525,700	0.7660 %	2 M ¥
VITAL KSK HOLDINGS, INC. 0.4596 %	315,400	0.4596 %	927 371 ¥
Noboru Kotani 0.2290 %	157,143	0.2290 %	462 048 ¥
CARENET, INC. 0.0874 %	60,000	0.0874 %	176 418 ¥
Nomura Asset Management Co., Ltd. 0.0860 %	59,000	0.0860 %	173 478 ¥
APS Asset Management (Japan) Co. Ltd. 0.0449 %	30,800	0.0449 %	90 561 ¥
KLP Kapitalforvaltning AS 0.0286 %	19,600	0.0286 %	57 630 ¥

Name	Equities	%	Valuation
SANBIO COMPANY LIMITED 0.00%	200	0.00%	588 $

SanBio Co., Ltd.

St. Luke Tower, 32/F 8-1 Akaishi-cho

104-0044, Tokyo

http://www.sanbio.com

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

419 JPY

Average target price

800 JPY

Spread / Average Target

+90.93%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SANBIO COMPANY LIMITED	-40.31%	183M
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103B
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28B
ARGENX SE	+1.69%	22.15B
BIONTECH SE	-17.37%	21.02B
GENMAB A/S	-9.30%	18.15B
WUXI APPTEC CO., LTD.	-41.01%	16.74B
BEIGENE, LTD.	-14.85%	16.05B
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68B
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17B

Bio Therapeutic Drugs